Clinical Trial

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-01; most recent amendment 2025-12-18.
Status change: Recruiting → Active, Not Recruiting 2025-12-18
Trial Details
NCT Number NCT07213583
Lead Sponsor Neurimmune AG
Collaborators: Alexion Pharmaceuticals, Inc.
Conditions Amyloid Transthyretin Cardiomyopathy
Enrollment 35 participants
Start Date 2025-08-28
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-19